Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (Q44880254)

7 December 2017

title

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice (English)

1 reference

7 December 2017

0 references

Emilia Ip

1 reference

7 December 2017

Geoff Farrell

1 reference

7 December 2017

Pauline Hall

1 reference

7 December 2017

Graham Robertson

1 reference

7 December 2017

Isabelle Leclercq

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

page(s)

1286-1296

1 reference

Liver fibrosis in overweight patients

7 December 2017

cites work

1 reference

7 January 2021

Nonalcoholic steatohepatitis: An expanded clinical entity

1 reference

7 January 2021

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

1 reference

7 January 2021

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

1 reference

7 January 2021

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

1 reference

7 January 2021

Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation

1 reference

7 January 2021

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice

1 reference

7 January 2021

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

1 reference

7 January 2021

Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate.

1 reference

7 January 2021

Peroxisomal leukotriene degradation: biochemical and clinical implications

1 reference

7 January 2021

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

1 reference

7 January 2021

Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging

1 reference

7 January 2021

Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3.

1 reference

7 January 2021

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

1 reference

7 January 2021

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis

1 reference

7 January 2021

4-hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression

1 reference

7 January 2021

Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression

1 reference

7 January 2021

Induction of Procollagen Type I Gene Expression and Synthesis in Human Hepatic Stellate Cells by 4-Hydroxy-2,3-Nonenal and Other 4-Hydroxy-2,3-Alkenals Is Related to Their Molecular Structure

1 reference

7 January 2021

Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis

1 reference

7 January 2021

Leptin is essential for the hepatic fibrogenic response to chronic liver injury

1 reference

7 January 2021

Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats

1 reference

7 January 2021

Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis

1 reference

7 January 2021

Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride

1 reference

7 January 2021

Etiopathogenesis of nonalcoholic steatohepatitis

1 reference

7 January 2021

Hepatic steatosis: innocent bystander or guilty party?

1 reference

7 January 2021

Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats

1 reference

7 January 2021

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

1 reference

7 January 2021

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

7 January 2021

PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells

1 reference

7 January 2021

ICAM-1 is involved in the mechanism of alcohol-induced liver injury: studies with knockout mice

1 reference

7 January 2021

Peroxisome proliferator-activated receptors and hepatic stellate cell activation

1 reference

7 January 2021

Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells.

1 reference

7 January 2021

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

1 reference

7 January 2021

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors

1 reference

7 January 2021

Experimental and human liver fibrogenesis

1 reference

7 January 2021

Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts

1 reference

7 January 2021

Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells

1 reference

7 January 2021

Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.

1 reference

7 January 2021

Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells.

1 reference

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

7 January 2021

Expression of connective tissue growth factor in experimental rat and human liver fibrosis

1 reference

7 January 2021

Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells

1 reference

7 January 2021

Peroxisome proliferator activated receptor-alpha expression in human liver.

1 reference

7 January 2021

Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans

1 reference

7 January 2021

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20170

1 reference

7 December 2017

1 reference